Fluid Biomarkers of Disease Burden and Cognitive Dysfunction in Progressive Supranuclear Palsy
Annals of Clinical and Translational Neurology · 2026-07 · 13 (7) · 1422-1432
DOI: 10.1002/acn3.70327 ↗Kurz gefasst
Fachartikel in der Zeitschrift Annals of Clinical and Translational Neurology, online erschienen am 28.01.2026. Verfasst von Roxane Dilcher und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosciences, School of Translational Medicine, Monash University, Melbourne, Victoria, Australia. Hauptthemen laut MEDLINE: Supranuclear Palsy, Progressive, tau Proteins, Cognitive Dysfunction, Neurofilament Proteins. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Brain Foundation, National Health and Medical Research Council, Medical Research Future Fund.
Abstract (Originalsprache)
Objective
Identifying objective biomarkers for progressive supranuclear palsy (PSP) is crucial to improving diagnosis and establishing clinical trial and treatment endpoints. This study evaluated fluid biomarkers in PSP versus controls and their associations with regional 18 F‐PI‐2620 tau‐PET, clinical, and cognitive outcomes.
Methods
Twenty‐four PSP patients and 11 age‐ and sex‐matched control subjects underwent Cerebrospinal fluid (CSF) and plasma assays of neurofilament light chain (NfL), glial fibrillary acidic protein (GFAP), and total tau (t‐tau) using SIMOA. Ratios (NfL/t‐tau, GFAP/t‐tau, GFAP/NfL) were calculated. Tau burden was quantified using PI‐2620 distribution volume ratio (DVR). Group comparisons and associations with tau‐PET, MRI, and cognition were tested using Wilcoxon tests, ROC analyses, and age‐ and sex‐adjusted linear models.
Results
PSP patients showed elevated NfL, GFAP levels, and higher NfL/t‐tau and GFAP/t‐tau ratios in CSF and plasma. CSF NfL/t‐tau best discriminated PSP from control subjects (AUC = 0.99, 95% CI [0.97–1.00]; optimal cut‐off: > 10), followed by CSF GFAP/t‐tau (AUC = 0.89, 95% CI [0.76–1.00]; > 104) and plasma NfL/t‐tau (AUC = 0.80, 95% CI [0.63–0.96]; 5.1). Plasma NfL/t‐tau correlated with tau‐PET DVR in the putamen ( β = 0.63; 95% CI [0.15–1.11]; p < 0.01) and pallidum ( β = 0.54, 95% CI [0.07–1.02]; p < 0.01) and predicted disease severity ( β = 0.61, 95% CI [0.19, 1.04]; p = 0.007) and processing speed ( β = 0.66, 95% CI [0.22, 1.10]; p = 0.006), explaining 35% and 33% of variance, respectively. Frontal MRI volume modestly improved prediction of processing speed (Δ R 2 adj = 0.23, p = 0.01), whereas tau‐PET did not.
Interpretation
Plasma NfL/t‐tau correlates with regional tau, disease severity, and cognition. Fluid biomarkers, complemented by PET and MRI, may support multimodal PSP diagnosis, monitoring, and trial stratification. Trial Registration Australian New Zealand Clinical Trials Registry: ACTRN12620001254987
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurosciences, School of Translational Medicine, Monash University, Melbourne, Victoria, Australia.
- Department of Medicine, Royal Melbourne Hospital, The University of Melbourne, Melbourne, Victoria, Australia.
- Melbourne School of Psychological Sciences, The University of Melbourne, Melbourne, Victoria, Australia.
- Department of Neurology, Alfred Hospital, Melbourne, Victoria, Australia.
- Department of Nuclear Medicine, Alfred Health, Melbourne, Victoria, Australia.
- School of Psychological Sciences, Turner Institute for Brain and Mental Health, Monash University, Clayton, Victoria, Australia.
ORCID-Profile: Roxane Dilcher, Stuart J McDonald, Matthew P Pase, Lucy Vivash
Förderung
- Brain Foundation
- National Health and Medical Research Council
- Medical Research Future Fund
- Monash University
- Alzheimer's Association
Zitieren
APA
Dilcher, R., Malpas, C. B., McDonald, S. J., O'Brien, W. T., Despott, C., Bertram, K. L., Pase, M. P., Frontzkowski, L., Law, M., O'Brien, T. J., & Vivash, L. (2026). Fluid Biomarkers of Disease Burden and Cognitive Dysfunction in Progressive Supranuclear Palsy. Annals of Clinical and Translational Neurology, 13(7), 1422-1432. https://doi.org/10.1002/acn3.70327
Vancouver
Dilcher R, Malpas CB, McDonald SJ, O'Brien WT, Despott C, Bertram KL, et al. Fluid Biomarkers of Disease Burden and Cognitive Dysfunction in Progressive Supranuclear Palsy. Annals of Clinical and Translational Neurology. 2026;13(7):1422-1432. doi:10.1002/acn3.70327
BibTeX
@article{Dilcher2026,
author = {Dilcher, Roxane and Malpas, Charles B and McDonald, Stuart J and O'Brien, William T and Despott, Craig and Bertram, Kelly L and Pase, Matthew P and Frontzkowski, Lukas and Law, Meng and O'Brien, Terence J and Vivash, Lucy},
title = {Fluid Biomarkers of Disease Burden and Cognitive Dysfunction in Progressive Supranuclear Palsy},
journal = {Annals of Clinical and Translational Neurology},
year = {2026},
volume = {13},
number = {7},
pages = {1422--1432},
doi = {10.1002/acn3.70327}
}
EUVIMED